In 2015, advances in immunotherapy for metastatic melanoma have come to fruition, with phase III data supporting the combination of ipilimumab and nivolumab as first-line therapy. Understanding the mechanisms involved in an effective antitumour immune response are now key to further advances. Several studies published in 2015 have increased our understanding of the complex relationships that exist between our immune system and malignancy.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Forefronts and hotspots evolution of the nanomaterial application in anti-tumor immunotherapy: a scientometric analysis
Journal of Nanobiotechnology Open Access 13 January 2024
-
Development of a novel immune-related lncRNA prognostic signature for patients with hepatocellular carcinoma
BMC Gastroenterology Open Access 07 November 2022
-
Current Trends of Immunotherapy in the Treatment of Cutaneous Melanoma: A Review
Dermatology and Therapy Open Access 02 August 2021
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723 (2010).
Robert, C. et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372, 320–330 (2015).
Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521–2532 (2015).
Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23–34 (2015).
Rizvi, N. A. et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124–128 (2015).
Van Allen, E. M. et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350, 207–211 (2015).
The Cancer Genome Atlas. Genomic classification of cutaneous melanoma. Cell 161, 1681–1696 (2015).
Herbst, R. S. et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515, 563–567 (2014).
Spranger, S., Bao, R. & Gajewski, T. F. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature 523, 231–235 (2015).
Snyder, A. et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371, 2189–2199 (2014).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
F.S.H. declares he has served as a consultant for Merck and Novartis, his institution receives research support from Bristol Myers Squibb, and his institution receives clinical trial support from Bristol Myers Squibb, Genentech, Merck and Novartis. E.I.B. declares no competing interests.
Rights and permissions
About this article
Cite this article
Buchbinder, E., Hodi, F. Immune-checkpoint blockade — durable cancer control. Nat Rev Clin Oncol 13, 77–78 (2016). https://doi.org/10.1038/nrclinonc.2015.237
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2015.237
This article is cited by
-
Forefronts and hotspots evolution of the nanomaterial application in anti-tumor immunotherapy: a scientometric analysis
Journal of Nanobiotechnology (2024)
-
Development of a novel immune-related lncRNA prognostic signature for patients with hepatocellular carcinoma
BMC Gastroenterology (2022)
-
A prodrug nanoplatform via esterification of STING agonist and IDO inhibitor for synergistic cancer immunotherapy
Nano Research (2022)
-
Enhanced anti-melanoma efficacy through a combination of the armed oncolytic adenovirus ZD55-IL-24 and immune checkpoint blockade in B16-bearing immunocompetent mouse model
Cancer Immunology, Immunotherapy (2021)
-
Nanoparticle-based approaches to target the lymphatic system for antitumor treatment
Cellular and Molecular Life Sciences (2021)